Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies

Journal of the American Aging Association

Volumn 25, Issue 2, 2002, Pages 87-99

  Ke Hua, H Zhu ^a   Brown, T A ^a   Thompson, D D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CHOLESTEROL; ESTRADIOL; ESTROGEN; GROWTH HORMONE; LASOFOXIFENE; PARATHYROID HORMONE; PROSTAGLANDIN E2; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE TURNOVER; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ESTROGEN THERAPY; FEMUR; HUMAN; LUMBAR VERTEBRA; METAPHYSIS; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; SOLEUS MUSCLE; TIBIA; TIME SERIES ANALYSIS; TRABECULAR BONE; UTERUS WEIGHT; WEIGHT GAIN;

EID: 0036556843     PISSN: 01619152     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11357-002-0007-y     Document Type: Article

References (67)

1. Melton III, L.J., Chrischilles, E.A., Cooper, C., Lane, A.W., and Riggs, B.L.: How many women have osteoporosis? J. Bone Miner. Res., 7:1005-1010, 1992.
2. Berg, R.L., Casell, J.S. (eds) Osteoporosis. The second fifty years: promoting health and preventing disability. National Academy Press, Washington DC, 1990, p.76-100.
3. Kessenich, C.R., and Rosen, C.J.: The pathophysiology of osteoporosis, in Osteoporosis: Diagnostic and Therapeutic Principles, edited by Rosen, C.J., Humana Press Inc., Totowa, New Jersey, 1996, pp.47-63.
4. Turner, R.T., Riggs, B.L., and Spelsberg, T.C.: Skeletal effects of estrogen. Endocrine Rev., 15:275-300, 1994.
5. Slemenda, C.W., Longcope, C., Zhou, L., Hui, S.L., Peacock, M., and Johnston, C.C.: Sex steroids and bone mass in older men. J. Clin. Invest., 100:1755-1759, 1997.
6. Greendale, G.A., Edelstein, S., and Barrett-Connor, E.: Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J. Bone Miner. Res., 12:1833-1843, 1997.
7. Khosla, S., Melton, L.J. III, Atkinson, E.J., O'Fallon, W.M., Klee, G.G., and Riggs, B.L.: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocronol. Metab., 83:2266-2274, 1998.
8. Riggs, B.L., Khosla, S., and Melton, L.J. III: A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res., 13:763-773, 1998.
9. Kanis, J.A., Melton, L.J. III, Christiansen, C., Johnson, C.C., and Khaltaev, N.: The diagnosis of osteoporosis. J. Bone Miner. Res., 9:1137-1141, 1994.
10. Riggs, B.L., and Melton, III L.J.: The prevention and treatment of osteoporosis. N. Engl. J. Med., 327:620-627, 1992.
11. Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D., and Cummings, S.R.: Estrogen replacement therepy and fractures in older women. Annals Inter. Med., 122:9-16, 1995.
12. Lobo, A.: Benefits and risks of estrogen replacement therapy. Am. J. Obstet. Gynecol., 173:982-990, 1995.
13. Maxim, P., Ettinger, B., and Spitalny, G.M.: Fracture protection provided by long-term estrogen treatment. Osteoporosis Int., 5:23-29, 1995.
14. Whitehead, M.I. and Fraser, D.: Controversies concerning the safety of estrogen replacement therapy. Am. J. Ob. Gyn., 156:1313-1322, 1987.
15. Colditz, G.A., Hankinson, S.E., Hunter, D.J., Willett, W.C., Manson, J.E., Stampfer, M.J., Hennekens, C., Rosner, B., and Speizer, F.E.: The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N. Eng. J. Med., 332:1589-1593, 1995.
16. Love, R.R., Bardon, H.S., Mazess, R.B., Epstein, S., and Chappell, R.J.: Effects of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Int. Med., 154:2585-2588, 1994.
17. Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Gullinan, G.J., Bendele, R., Kauffman, R.R., Bensch, W.R., Frolik, C.A., Termine, J.D., and Bryant, H.U.: Raloxifene (LY 139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest., 93:63-69, 1994.
18. Bryant, H.U., Glasebrook, A.L., Yang N.N., and Sato, M.: A pharmacological review of raloxifene. J. Bone Miner. Metab., 14:1-9, 1996.
19. Ke, H.Z., Simmons, H.A., Pirie, C.M., Crawford, D.T., and Thompson, D.D.: Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology, 136:2435-2441, 1995.
20. Ke, H.Z., Chen, H.K., Simmons, H.A., Qi, H., Crawford, D.T., Pirie, C.M., Chidsey-Frink, K.L., Ma, Y.F., Jee, W.S.S., and Thompson, D.D.: Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone, 20:31-39, 1997.
21. Bryant, H.U., and Dere, W.H.: Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proce. Society Exp. Biol. Medicine, 217:45-52, 1998.
22. Johnston, C.C., Bjarnason, N.H., Cohen, F.J., Shah, A., Lindsay, R., Mitlak, B.H., Huster, W., Draper, M.W., Harper, K.D., Heath, H., Gennari, C., Christiansen, C., Arnaud, C.D., and Delmas, P.D.: Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch. Intern. Med., 160:3444-34450, 2000.
23. Ettinger, B., Black, D.M., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., Christiansen, C., Delmas, P.D., Zanchetta, J.R., Stakkestad, J., Gluer, C.C., Krueger, K., Cohen, F.J., Eckert, S., Ensrud, K.E., Avioli, L.V., Lips, P., and Cummings, S.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA, 282:637-645, 1999.
24. Cummings, S., Eckert, S., Krueger, K., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., Lippman, M.E., Black, D.M., Glusman, J.E., Costa, A., and Jordan, V.G.: The effects of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189-2197, 1999.
25. Agnusdei, D., and Compston, J.: SERMs, a novel option to maintain health in the postmenopause. London, UK, Martin Dunitz Ltd, 2000, pp. 49-61.
26. McDonnell, D.P.: Selective estrogen receptor modulators (SERMs): a first step in the development of perfect hormone replacement therapy regimen. J. Soc. Gynecol. Investig., 7:S10-S15, 2000.
27. Ke, H.Z., Paralkar, V.M., Grasser, W.A., Crawford, D.T., Qi, H., Simmons, H.A., Pirie, C.M., Chidsey-Frink, K.L., Owen, T.A., Smock, S.L., Chen, H.K., Jee, W.S.S., Cameron, K.O., Rosati, R.L., Brown, T.A., DaSilva-Jardine, P., and Thompson, D.D.: Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models. Endocrinology, 139:2068-2076, 1998.
28. Ke, H.Z., Qi, H., Crawford, D.T., Chidsey-Frink, K.L., Simmons, H.A., and Thompson, D.D.: Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology, 141:1338-1344, 2000.
29. Ke, H.Z., Qi, H., Chidsey-Frink, K.L., Crawford, D.T., and Thompson, D.D.: Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J. Bone Miner. Res., 16:765-773, 2001.
30. Cohen, L.A., Pittman, B., Wang, C.-X., Aliaga, C., Yu, L., and Moyer, J.D.: LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-methylurea-induced rat mammary tumor model. Cancer Research, 61:8683-8688, 2001.
31. Petersen, D.N., Tkalcevic, G.T., Koza-Taylor, P.H., Turi, T.G., and Brown, T.A.: Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues. Endocrinology, 139:1082-92, 1998.
32. Leake, R.E., and Habib, F.: Steroid hormone receptors: assay and characterization. In Steroid Hormones: A Practical Approach. Green, B. and Leake, R.E. (eds), Oxford, IRL Press Ltd., 1987, pp. 67-92.
33. Wijayaratne, A.L., Nagel, S.C., Paige, L.A., Christensen, D.J., Norris, J.D., Fowlkes, D.M., and McDonnell, D.P.: Comparative analyses of mechanistic differences among antiestrogens. Endocrinology, 140:5828-40, 1999.
34. Tzukerman, M.T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M.G., Stein, R.B., Pike, J.W., and McDonnell, D.P.: Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology, 8:21-30, 1994.
35. McDonnell, D.P., Clemm, D.L., Hermann, T., Goldman, M.E., and Pike, J.W.: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocrinology, 9:659-69, 1995.
36. O'Brien, M.L., Park, K., In, Y., and Park-Sarge, O.K.: Characterization of estrogen receptor-beta (ERbeta) messenger ribonucleic acid and protein expression in rat granulosa cells. Endocrinology, 140:4530-41, 1999.
37. Kalu, D.N.: The ovariectomized rat model of post-menopausal bone loss. Bone and Mineral, 15:175-192, 1991.
38. Wronski, T.J., and Yen, C.-F.: The ovariectomized rat model as an animal model for postmenopausal bone loss. Cells Materials, suppl. 1:69-74; 1991.
39. Frost, H.M. and Jee, W.S.S.: On the rat model of human osteopenias and osteoporosis. Bone and Mineral, 18:227-236, 1992.
40. Jee, W.S.S. and Yao, W.: Overview: animal models of osteopenia and osteoporosis. J. Musculoskel. Neuron. Interact., 1:193-207;2001.
41. Chen, H.K., Ke, H.Z., Lin, C.H., Ma, Y.F., Qi, H., Crawford, D.T., Pirie, C.M., Simmons, H.A., Jee, W.S.S., and Thompson, D.D.: Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone, 17 (suppl.): 175S-179S, 1995.
42. Ke, H.Z., Chen, H.K., Qi, H., Pirie, C.M., Simmons, H.A., Ma, Y.F., Jee, W.S.S., and Thompson, D.D.: Effects of Droloxifene on prevention of cancellous bone loss and bone turnover of the axial skeleton of aged, ovariectomized rats. Bone, 17:491-496, 1995.
43. Chen, H.K., Ke, H.Z., Jee, W.S.S., Ma, Y.F., Pirie, C.M., Simmons, H.A., and Thompson, D.D.: Droloxifene Prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study. J. Bone and Miner. Res., 10:1256-1262, 1995.
44. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis (draft). Division of Metabolism and Endocrine Drug Products, U. S. Food and Drug Administration, 1994.
45. Thompson, D.D., Simmons, H.A., Pirie, C.M., and Ke, H.Z.: FDA guidelines and animal models for osteoporosis. Bone, 17(suppl. 4):125S-133S, 1995.
46. Dempster, D.W., Cosman, F., Parisien, M., and Shen, V.: Anabolic action of parathyroid hormone on bone. Endocrine Review, 14:690-709; 1993.
47. Jee, W.S.S. and Ma, Y.F.: The in vivo anabolic actions of prostaglandins in bone. Bone, 21:297-304; 1997.
48. Ke, H.Z., Shen, V.W., Qi H., Crawford, D.T., Wu, D.D., Liang, X.G., Chidsey-Frink, K.L., Pirie, C.M., Simmons, H.A., and Thompson, D.D.: Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia. Bone, 23:249-255; 1998.
49. Ke, H.Z., Crawford, D.T., Qi, H., Pirie, C.M., Simmons, H.A., Chidsey-Frink, K.L., Chen, H.K., Jee, W.S.S. and Thompson, D.D.: Droloxifene does not blunt the bone anabolic effects of prostaglandin E2 but maintains the prostaglandin E2-restored bone in aged, ovariectomized rats. Bone, 24:41-47; 1999.
50. Ke, H.Z., Chidsey-Frink, K.L., Crawford, D.T., Qi, H., Simmons, H.A., and Thompson, D.D.: Co-treatment of lasofoxifene (CP-336,156) and estrogen inhibits estrogen's effect in the uterus but maintains the bone protective effects in ovariectomized rats. J. Bone and Mineral Res., 15 (suppl. 1) S310, 2000.
51. Ke, H.Z., Chidsey-Frink, K.L., Simmons, H.A., Crawford, D.T., Qi, H., Pirie, C.M., Shen, V. and Thompson, D.D.: CP-336,156, A New Selective Estrogen Receptor Modulator (SERM), Enhances the Effects of Parathyroid Hormone in Restoring Bone Mass and Strength in Ovariectomized Rats. J. Bone and Mineral Res., 13 (suppl. 1) S495, 1998.
52. 2) in Restoring Bone Mass and Bone Strength in Ovariectomized Rats. J. Bone and Mineral Res., 13 (suppl. 1) S609, 1998.
53. Ohlsson, C., Bengtsson, B.-A., Isaksson, O.G.P., Andreassen, T.T., and Slootweg, M.C.: Growth hormone and bone. Endocrine Review 19:55-79,1998.
54. Pan, L.C., Carpino, P.A., Lefker, B.A., Ragan, J.A., Toler, S.M., Pettersen, J.C., Nettleton, D.O., Ng, O.C., Pirie, C.M., Chidsey-Frink, K., Lu, B., Nickerson, D.F., Tess, D.A., Mullins, M.A., MacLean, D.B., DaSilva-Jardine, P.A., and Thompson, D.D.: Preclinical pharmacology of CP-424391, an orally active pyazolidinone-piperidine growth hormone secretagogue. Endocrine, 14:121-132, 2001.
55. Ke, H.Z., Li, M., Pan, L.C., Yu, L., MacLean, D.B., and Thompson, D.D.: Combined administration of a growth hormone secretagogue (GHS) and a new selective estrogen receptor modulator (SERM) increases bone and muscle mass and decreases total serum cholesterol in ovariectomized rats. J. Bone and Mineral Res., 13 (suppl. 1) S390, 1998.
56. Kanis, J.A., and Pitt, F.A.: Epidemiology of osteoporosis. Bone, 13:S7-S15, 1992.
57. Cooper, C., Campion, G., and Melton, L.J.: Hip fractures in the elderly: a world-wide projection. Osteoporosis Int., 2:285-289, 1992.
58. Slemenda, C.W., Longcope, C., Zhou, L., Hui, S.L., Peacock, M., and Johnston, C.C.: Sex steroids and bone mass in older men. J. Clin. Invest., 100:1755-1759, 1997.
59. Greendale, G.A., Edelstein, S., and Barrett-Connor, E.: Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J. Bone Miner. Res., 12:1833-1843, 1997.
60. Khosla, S., Melton, L.J. III, Atkinson, E.J., O'Fallon, W.M., Klee, G.G., and Riggs, B.L.: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocronol. Metab., 83:2266-2274, 1998.
61. Riggs, B.L., Khosla, S., and Melton, L.J. III: A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postemenopausal women and contributes to bone loss in aging men. J. Bone Mineral Res., 13:763-773, 1998.
62. Ke, H.Z., Crawford, D.T., Qi, H., Chidsey-Frink, K.L., Simmons, H.A., Li, M., Jee, W.S.S., Thompson, D.D. Long-term effects of aging and orchidectomy on bone and body composition in rapidly growing male rats. J. Musculoskel. Neuron. Interact., 1:215-224, 2001.
63. Erben, R.G., Eberle, J., Stahr, K., and Goldberg, M.: Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J. Bone Miner. Res., 15:1085-1098, 2000.
64. Wakley, G.K., Schutt, H.D., Hannon, K.S., and Turner, R.T.: Androgen treatment prevents loss of cancellous bone in the orchidectomized rats. J. Bone Miner. Res., 6:325-330, 1991.
65. Vanderscheuren, D., Van Herck, D., Suiker, A.M.H., Visser, W.J., Schot, L.P.C., and Bouillon, R.: Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology, 130:2906-2916, 1992.
66. Li, M., Jee, W.S.S., Ke, H.Z., Tang, L.Y., Ma, Y.F., Liang, X.G., and Setterberg, R.B.: Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats. J. Bone Miner. Res., 10:66-73, 1995.
67. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90:1371-1388, 1998.